Paraneoplastic dermatomyositis and prostate cancer: Myopathy regression under cancer-directed therapy

Mafalda Miranda Baleiras, Luis Maduro, Carolina Vasques, Filipa Ferreira, Marta Mesquita Pinto, Ana Martins
Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, Portugal

Abstract

Prostate cancer is the second most frequent malignancy in men worldwide and the fifth leading cause of death. Dermatomyositis (DM) is a rare idiopathic inflammatory myopathy characterized by musculocutaneous manifestations. However, DM can also present as a paraneoplastic syndrome of an underlying neoplasm. We report a case of a 65-year-old man diagnosed with prostate adenocarcinoma in the setting of severe dysphagia, muscle weakness and a facial erythematous rash. At first, the DM-related symptoms resolved with the initial treatment for the underlying malignancy. Yet, they flared up as the tumor progressed. To sum up, DM is a rare systemic disorder with unknown etiology. There is a well-established association between DM and malignancy. Malignancy-headed therapy can improve DM manifestations and the recurrence of DM symptoms may act as an early warning of malignancy relapse.

Case Report

A 65-year-old Cape Verdean, with a past medical history of type 2 diabetes and hypertension, presented with a five-month history of progressive asthenia, dysphagia and tetraparesis. He reported no other systemic symptoms and denied a family history of malignancy. On examination, the subject showed a fixed painless 2 cm-long left supraclavicular lymph node and a mild periorbital violaceous erythema. Neurological examination revealed reduced symmetrical proximal strength in both upper and lower limbs (3/5). He was unable to rise independently from a seated position and displayed a waddling gait. General examination was unremarkable.

A clinical diagnosis of DM was made, supported on raised creatine kinase (CK) of 1450 U/L (reference range <190) and lactate dehydrogenase (LDH) of 580 U/L (reference range 135-225). Myositis-specific antibody panel was positive for the anti-nuclear matrix protein 2 (NXP2), thus corroborating this diagnosis. On further investigation, a computed tomography (CT) scan of the chest, abdomen and pelvis revealed a nodular prostate and enlarged left iliac, para-aortic and supraclavicular lymph nodes (Figure 1). A transperineal prostate biopsy showed a Gleason grade group 5 adenocarcinoma. Therefore, the patient was diagnosed with very high-risk metastatic hormone-sensitive prostate cancer with paraneoplastic dermatomyositis.

Following DM diagnosis, physical rehabilitation, and a five-day course of 2 g/kg bodyweight Intravenous Immunoglobulin (IVIG) was prescribed as the initial therapy. Albeit with some improvement of the skin lesions and prednisolone (10 mg/day) and androgen deprivation therapy made up of leuprorelin (22.5 mg every 12 weeks) and bicalutamide (50 mg/day). His weakness and rash resolved and CK levels normalized as the prostate-specific antigen (PSA) started to decrease progressively from 77.6 ng/ml to 14.8 ng/mL. He finally managed to eat solid consistent food and became fully independent in his daily life activities.

Eight months after the prostate cancer-
directed therapy had begun, blood tests showed elevation of PSA levels (to 40 ng/mL). At the same time, the patient complained again of muscle weakness in the limbs – yet, the neurologic exam revealed no deficit of muscle strength. One month later, a recurrence of the DM clearly emerged including proximal weakness, dysphagia, diffuse myalgia and raised CK (439 U/L). A CT scan was conducted and revealed ganglionar progression (Figure 2). The patient was then administered with docetaxel-based (75 mg/m² every 21 days) systemic chemotherapy. After the first cycle of chemotherapy, his muscle claims decreased remarkably. The authors keep monitoring this case closely.

Discussion

DM typically presents with characteristic skin lesions and progressive symmetrical proximal muscle weakness. Myopathy is present in approximately 80% of patients with DM and is usually painless. Dysphagia, dysphonia and aspiration pneumonia may also occur and are associated with a poor prognosis. In addition to pathognomonic cutaneous findings, such as Gottron’s papules and heliotrope rash, DM often presents with periungual telangiectasias, poikiloderma and cuticular overgrowth. Lesions can precede or follow myositis and may be pruritic, which normally disturbs life quality.

The European League Against Rheumatism and the American College of Rheumatology (EULAR/ACR) criteria for IIM, published in 2017, are a highly sensitive and specific probability-based classification system. A classification tree is then used to assign IIM subtypes. Although its pathogenesis remains unclear, several genetic, immunologic and environmental factors are thought to play a role in DM development. Approximately 70% of DM patients have myositis-specific autoantibodies (MSA) in circulation. Their presence matters for prognosis and clinical management inasmuch as they are associated with distinct clinical phenotypes.

Paraneoplastic dermatomyositis was first described in 1916 and accounts for approximately 30% of dermatomyositis cases. The risk of malignancy is highest within a year of DM diagnosis and remains high for up to five years. A neoplasm can precede, coincide with or follow the diagnosis of DM. Although the precise link between malignancy and DM is poorly understood, cellular and humoral immunologic abnormalities have been suggested. The most frequent associated malignancies are breast, ovarian, lung, colorectal and Hodgkin’s lymphoma. Malignancy-associated DM risk factors are: age over 60, male gender, dysphagia, skin necrosis, cutaneous vasculitis, rapid onset (< weeks), elevated CK and C-reactive protein and an increase in the erythrocyte sedimentation rate (ESR). The association between DM and malignancy is particularly strong in those patients with antibodies to transcription intermediary factor 1γ (TIF1γ) or nuclear matrix protein 2 (NXP2), some of the MSA recently discovered.

DM treatment goals are the improvement of daily living activities through increased muscle strength and the alleviation of extramuscular manifestations. Systemic corticosteroids are the mainstay of therapy. Second-line therapeutic regimens include methotrexate and azathioprine. If resistance to therapy is developed, rituximab or intravenous immunoglobulin can be used. Supplemental nutrition and rehabilitation are also essential to improve mus-

Figure 1. Image A: Oblique axial CT plane shows an enlarged and asymmetric prostate (P) with prominent nodular densities extending posteriorly into the periprostatic space. Transrectal prostate biopsy revealed cancer in this area. Image B: Sagittal CT plane. Image C: different oblique axial CT plane. These latter planes demonstrate the tumor (T) also spreading superiorly, with infiltration of fat between the left seminal vesicle (SV) and the rectum wall (R) and loss of the fat planes between these structures. CT is not accurate to characterize locally the prostatic cancer. MRI is the imaging method for regional staging, but the presence of disseminated disease, shown by non-regional/distant metastatic adenopathies (Adp), made MRI unnecessary.

Figure 2. CT images. The right image (Axial CT scan) shows progressive disease with an increase of retroperitoneal lymph nodes, comparing to the CT performed nine months before (left image).
cle strength and endurance. Some studies report improvement of DM symptoms with cancer treatment and the relation of myopathy recurrence with neoplasm relapse, thus supporting a paraneoplastic nature. There are also reports highlighting tumor resolution after treatment for the underlying malignancy, thereby avoiding the use of corticotherapy and its side effects.

In the current case, the clinical suspicion for DM arose from typical features such as scapular and pelvic girdles muscle weakness, erythematous skin rash and elevated CK. The anti-NXP2 positivity also supported the diagnosis, since this DM-specific autoantibody is present in up to 30% of adult-onset DM. Anti-NXP2 antibodies are associated with heliotrope rash and more extensive myopathy including dysphagia, as observed in our patient. Fiorentino et al. reported that 24% of anti-NXP2 positive DM patients had malignancy. This association with cancer is also supported in a Japanese cohort study showing that three out of eight anti-NXP2 positive patients had advanced stage malignancy. The patient hereby considered also met other risk factors for cancer such as male gender, ageing, dysphagia and diabetes. There were two developments in his condition in line with the paraneoplastic origin of DM: i) the significant clinical enhancement with the cancer-directed therapy; and ii) the DM recurrence coincided with the tumor progression.

Conclusions

To sum up, DM is a rare systemic disorder with unknown etiology. There is a well-established association between DM and malignancy. Thus, the chance of an underlying neoplasm should be ruled out in newly diagnosed DM especially in high-risk patients. A coordinated multidisciplinary approach is essential for early diagnosis and timely treatment to improve the malignancy-associated DM prognosis.

The treatment of the underlying malignancy will usually result in symptom resolution in cases of paraneoplastic DM. It is important to keep in mind that myositis manifestations may relapse in the setting of recurrent or aggravated malignancy. These patients should therefore be monitored closely.

References

1. Baijens LW, Manni JJ. Paraneoplastic syndromes in patients with primary malignancies of the head and neck. Four cases and a review of the literature. Eur Arch Otorhinolaryngol 2006;263:32-6.
2. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001;85:41-5.
3. Olazagasti JM, Baez PJ, Wetter DA, Ernesto FC. Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol 2015;16:89-98.
4. Motomura K, Yamashita H, Yamada S, et al. Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study. Rheumatol Int 2019;39:1733-9.
5. Rawla P. Epidemiology of Prostate Cancer. World J Oncol 2019;10:63-8.
6. Schmidt J. Current Classification and Management of Inflammatory Myopathies. J Neuromuscul Dis 2018;5:109-29.
7. Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015;372:1734-47.
8. Bottai M, Tjärnlund A, Santoni G, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open 2017;3:e000507.
9. DeWane ME, Waldman R, Lu J. Dermatomyositis: Clinical Features and Pathogenesis. J Am Acad Dermatol 2020;82:267-81.
10. Calvão J, Azeiteiro ARI, Gonçalo M. A importância dos novos autoanticorpos específicos da dermatomiosite. J Portug Soc Dermatol Venereol 2019;77:15-24.
11. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96–100.
12. Kang E, Lee S, Ascherman D, et al. Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatol 2016;55:1631-41.
13. Jakubaszek M, Kwiatkowska B, Maślińska M. Polymyositis and dermatomyositis as a risk of developing cancer. Reumatologia 2015:53:101-5.
14. Waldman R, DeWane ME, Lu J. Dermatomyositis: Diagnosis and Treatment. J Am Acad Dermatol 2020;82:283-96.
15. Castro AS, Barroso A, Parente B. Dermatomiosite como primeira manifestação de uma neoplasia pulmonar. Rev Port Pneumol 2013;19:179-83.
16. Lin C, Ying Z, Sijing C. Spontaneous resolution of dermatomyositis associated with fallopian-tube carcinoma following staging surgery: A case report. Medicine 2019;98:e14530.
17. Orth T, Galle PR, Mayet WJ. Severe dermatomyositis associated with lymph node recurrence of an endometrial carcinoma. J Clin Rheumatol 1999;5:41-2.
18. Nakashima R. Clinical significance of myositis-specific autoantibodies. Immunol Med 2018;41:3,103-12.